Organization (Academic)
Kamuzu University of Health Sciences
ClinicalTrials.gov lists Kamuzu University of Health Sciences as lead sponsor of 13 trials. It has 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Kamuzu University of Health Sciences: 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (54)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Malaria | 16 |
| Malnutrition | 13 |
| Growth Disorders | 8 |
| Malaria, Falciparum | 7 |
| Severe Acute Malnutrition | 6 |
Showing 5 of 54 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 7 |
| 2023 | 6 |
| 2022 | 5 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 7 |
| 2018 | 6 |
| 2017 | 6 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ceftriaxone v penicillin and gentamicin | 1 |
| Artemether + Lumefantrine | 1 |
| Mosquirixs | 1 |
| Glycerol | 1 |
| Acetaminophen | 1 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
Journals published in (102)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The American journal of clinical nutrition | 19 |
| The Journal of nutrition | 15 |
| Malaria journal | 12 |
| The Lancet. Global health | 10 |
| The American journal of tropical medicine and hygiene | 8 |
Showing 5 of 102 journals.
Financing and grant events (8)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-17 | NIH grant | 278,212 | Reporter |
| 2025-09-14 | NIH grant | 108,804 | Reporter |
| 2025-09-08 | NIH grant | 754,657 | Reporter |
| 2025-09-07 | NIH grant | 304,400 | Reporter |
| 2025-08-12 | NIH grant | 266,442 | Reporter |
Showing 5 of 8 events.
Organization relationships (71)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 12 |
| Wellcome Trust | Co sponsors trial with | 8 |
| Liverpool School of Tropical Medicine | Co sponsors trial with | 8 |
| University System of Maryland | Co sponsors trial with | 6 |
| Tampere University | Co sponsors trial with | 5 |
Showing 5 of 71 relationships.
Latest dated events (90)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-17 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-14 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-08 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 90 events.
Biomarker capability evidence (5)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ENOSF1 | Trial collaborator | Named in trial inclusion criteria |
| ENOSF1 | Trial collaborator | Named in trial inclusion criteria |
| ENOSF1 | Trial collaborator | Mentioned in trial text |
| ENOSF1 | Trial collaborator | Mentioned in trial text |
| MPI | Trial collaborator | Mentioned in trial text |
Biomarkers this organization publishes on (33)
Shown in this order: most publications first.
Showing 5 of 33 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.